Corient Private Wealth
VNDA icon

Corient Private Wealth’s Vanda Pharmaceuticals VNDA Stock Holding History

Corient Private Wealth’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$626K Sell
102,359
-269
-0.3% -$1.76K ﹤0.01% 2075
2026
Q1 		$709K Buy
+102,628
New +$791K ﹤0.01% 1840
2024
Q1 		– Sell
-11,492
Closed -$48.5K – 2374
2023
Q4 		$48.5K Buy
+11,492
New +$46.4K ﹤0.01% 2199

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Corient Private Wealth's VNDA Position: Q2 2026 in Review

Corient Private Wealth reduced its Vanda Pharmaceuticals (VNDA) stake by 0.26% in Q2 2026, selling an estimated $1.76K and leaving 102,359 shares worth $626K. The position accounts for ﹤0.01% of the portfolio, ranked #2075.

Corient Private Wealth first reported a position in VNDA in Q4 2023 and has held it in 3 quarters since. The position peaked at $709K in Q1 2026. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Corient Private Wealth held 102,359 shares of Vanda Pharmaceuticals worth $626K as of Q2 2026.
  • Corient Private Wealth sold 269 Vanda Pharmaceuticals shares in Q2 2026, an estimated $1.76K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2075 holding.
  • Corient Private Wealth first reported a position in Vanda Pharmaceuticals in Q4 2023 and has held it in 3 quarters since.
  • Corient Private Wealth's Vanda Pharmaceuticals position peaked at $709K in Q1 2026.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.